Factors associated with drug-induced visual hallucinations in Parkinson's disease

Journal of Neurology

Volumn 252, Issue 10, 2005, Pages 1223-1228

  Papapetropoulos, Spiridon ^a,b   Argyriou, Andreas A ^b   Ellul, John ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Clinical phenotype; Hallucinations; Parkinson's disease; Risk factors

Indexed keywords

AMANTADINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DELUSION; DEMENTIA; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; DISEASE DURATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DYSKINESIA; FEMALE; HUMAN; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL HEALTH; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARAMETRIC TEST; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION; VIVID DREAM;

AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; FEMALE; GREECE; HALLUCINATIONS; HUMANS; INTERVIEWS; LEVODOPA; LOGISTIC MODELS; MALE; MIDDLE AGED; PARKINSON DISEASE; PREVALENCE; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; VISUAL ACUITY;

EID: 26644440164     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0840-x     Document Type: Article

References (37)

1. Aarsland D, Ballard C, Larsen JP, et al. (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 16(5):528-536
2. Aarsland D, Larsen JP, Cummins JL, et al. (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56(5):595-601
3. American Psychiatric Association (1987) Diagnostic and Statistical Manual for Psychiatric Disorders. Revised third edition (ed) American Psychiatric Association. Washington, DC
4. Barclay CL, Hildebrand K, Gray P, et al. (1997) Risk factors for the development of psychosis in Parkinson's disease. Mov Disord 12(Suppl. 1):108
5. Barnes J, David AS (2001) Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70(6):727-733
6. Carter JH, Stewart BJ, Archbold PG, et al. (1998) Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord 13(1):20-28
7. Fahn S, Elton RL, Committee (1987) MotUd, Unified Parkinson's disease rating scale in Recent developments in Parkinson's disease. Macmillan healthcare information, pp 153-163
8. Fenelon G, Mahieux F, Huon R, et al. (2000) Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4):733-745
9. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189-198
10. Goetz CG, Pappert EJ, Blasucci LM, et al. (1998) Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50(2):515-517
11. Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45(4):669-671
12. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43(11):2227-2229
13. Goetz CG, Vogel C, Tanner CM, et al. (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51(3):811-814
14. Graham JM, Grunewald RA, Sagar HJ (1997) Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 63(4):434-440
15. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427-442
16. Holroyd S (1996) Visual hallucinations in a geriatric psychiatry clinic: prevalence and associated diagnoses. J Geriatr Psychiatry Neurol 9(4):171-175
17. Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 70(6):734-738
18. Hughes AJ, Daniel SE, Kilford L, et al. (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases (see comments). J Neurol Neurosurg Psychiatry 55(3):181-184
19. Inzelberg R, Kipervasser S, Korczyn AD (1998) Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 64(4):533-535
20. Ismail MS, Richard IH (2004) A reality test: How well do we understand psychosis in Parkinson's disease? J Neuropsychiatry Clin Neurosci 16(1):8-18
21. McKeith I, Mintzer J, Aarsland D, et al. (2004) Dementia with Lewy bodies. Lancet Neurol 3(1):19-28
22. McKeith IG, Fairbairn AF, Bothwell RA, et al. (1994) An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 44(5):872-877
23. McKeith IG, Galasko D, Kosaka K, et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113-1124
24. Morris SK, Olichney JM, Corey-Bloom J (1998) Psychosis in Dementia With Lewy Bodies. Semin Clin Neuropsychiatry 3(1):51-60
25. rd, Klawans HL (1978) Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 135(6):669-675
26. Naimark D, Jackson E, Rockwell E, et al. (1996) Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 44(3):296-299
27. Oertel WH (2000) Pergolide versus L-dopa (PELMOPET). Mov Disord. 15(Suppl. 3):4
28. Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284(15):1931-1938
29. Perry EK, Marshall E, Kerwin J, et al. (1990) Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55(4):1454-1456
30. Rascol O, Brooks DJ, Korczyn AD, et al. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342(20):1484-1491
31. Richard IH, Papka M, Rubio A, et al. (2002) Parkinson's disease and dementia with Lewy bodies: one disease or two? Mov Disord 17(6):1161-1165
32. Rinne UK, Bracco F, Chouza C, et al. (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55(Suppl 1):23-30
33. Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson disease. Arch Neurol 53(12):1265-1268
34. Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson's disease, in: Gillingham FD (ed) Third symposium of Parkinson's disease, IMl, Livingstone: Edinburgh, pp 152-157
35. Shergill SS, Walker Z, Le Katona C (1998) A preliminary investigation of laterality in Parkinson's disease and susceptibility to psychosis. J Neurol Neurosurg Psychiatry 65(4):610-611
36. Tanner CM, Vogel C, Goetz CG (1983) Hallucinations in Parkinson's disease: a population study. Ann Neurol 14:136
37. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10-13